@article{8ad24bbf791946ea96d8d9af82d94a72,
title = "Preclinical Screening for Treatments for Infantile Spasms in the Multiple Hit Rat Model of Infantile Spasms: An Update",
abstract = "Infantile spasms are the typical seizures of West syndrome, an infantile epileptic encephalopathy with poor outcomes. There is an increasing need to identify more effective and better tolerated treatments for infantile spasms. We have optimized the rat model of infantile spasms due to structural etiology, the multiple-hit rat model, for therapy discovery. Here, we test three compounds administered after spasms induction in the multiple hit model for efficacy and tolerability. Specifically, postnatal day 3 (PN3) male Sprague-Dawley rats were induced by right intracerebral injections of doxorubicin and lipopolysaccharide. On PN5 p-chlorophenylalanine was given intraperitoneally (i.p.). Daily monitoring of weights and developmental milestones was done and rats were intermittently video monitored. A blinded, randomized, vehicle-controlled study design was followed. The caspase 1 inhibitor VX-765 (50–200 mg/kg i.p.) and the GABAB receptor inhibitor CGP35348 (12.5–100 mg/kg i.p.) each was administered in different cohorts as single intraperitoneal injections on PN4, using a dose- and time-response design with intermittent monitoring till PN5. 17β-estradiol (40 ng/g/day subcutaneously) was given daily between PN3-10 and intermittent monitoring was done till PN12. None of the treatments demonstrated acute or delayed effects on spasms, yet all were well tolerated. We discuss the implications for therapy discovery and challenges of replication trials.",
keywords = "CGP35348, Drug resistant, Epilepsy, Estradiol, Replication, Seizure, VX-765",
author = "Galanopoulou, {Aristea S.} and Mowrey, {Wenzhu B.} and Wei Liu and Qianyun Li and Oleksii Shandra and Mosh{\'e}, {Solomon L.}",
note = "Funding Information: ASG reports grants from NINDS-R01NS91170, NINDS-1U54NS100064, Department of Defense (W81XWH-13-1-0180), and the Infantile Spasms Initiative from CURE (Citizens United for Research in Epilepsy), and acknowledges also research funding from the Heffer Family and the Segal Family Foundations and the Abbe Goldstein/Joshua Lurie and Laurie Marsh/Dan Levitz families. WBM reports grant support from NINDS-1U54NS100064, Department of Defense (W81XWH-13-1-0180), the Infantile Spasms Initiative from CURE (Citizens United for Research in Epilepsy), and the Rett Syndrome Research Trust. SLM is the Charles Frost Chair in Neurosurgery and Neurology. He reports grants NINDS-NS020253, NINDS-NS43209, NINDS-NS45911, NINDS-1U54NS100064 and a grant from the US Department of Defense (W81XWH-13-1-0180), CURE Infantile Spasms Initiative grant and donations from the Heffer Family and the Segal Family Foundations and the Abbe Goldstein/Joshua Lurie and Laurie Marsh/Dan Levitz families. SLM holds a US patent for the multiple hit rat model (#7863499); no financial profits or conflicts have ensued as a result of this patent. We would like to thank Charles B. Hall, PhD (Division of Biostatistics, Albert Einstein College of Medicine) who performed the power analysis on the repeat administration treatment studies. We also wish to acknowledge the excellent technical assistance of Mrs Hong Wang. Publisher Copyright: {\textcopyright} 2017, Springer Science+Business Media New York.",
year = "2017",
month = jul,
day = "1",
doi = "10.1007/s11064-017-2282-0",
language = "English (US)",
volume = "42",
pages = "1949--1961",
journal = "Neurochemical Research",
issn = "0364-3190",
publisher = "Springer New York",
number = "7",
}